多笔里程碑款项到账，中国创新药“兑现价值” ，1.5万亿美元大市场加速成长

Group 1 - The core viewpoint of the articles highlights the acceleration of innovation in the biopharmaceutical sector in Guangzhou, focusing on monoclonal antibodies, vaccines, blood products, and diagnostic reagents, aiming for high-end and international development [1] - By 2025, the total value of China's innovation drug license-out transactions is expected to reach $135.655 billion, with an upfront payment of $7 billion and a total of 157 transactions, significantly surpassing the 2024 figures of $51.9 billion and 94 transactions [1] - The collaboration between Bai Li Tian Heng and Bristol-Myers Squibb (BMS) resulted in a milestone payment of $250 million, setting a record for domestic ADC projects, while other partnerships are also expected to yield substantial payments [1] Group 2 - The National Medical Products Administration reports that by the first half of 2025, China's innovation drug license-out transaction scale is nearing one-third of the global market, with 210 innovative drugs approved during the "14th Five-Year Plan" period [2] - The "15th Five-Year Plan" suggests that specialized funds for cell therapy and gene editing will exceed 30 billion yuan, indicating a strong future for these sectors [2] - The domestic innovation drug market is projected to grow, with the share of overseas revenue increasing from 15% in 2025 to 30% by 2030, contributing to a new growth driver for the industry [2]